28:31 Perspective on the updated TNM classification: Is there a role for histology or markers? HMP Education
21:16 Locally advanced NSCLC: Choice and sequencing of systemic agents in combined modality therapy HMP Education
20:58 Update on rare species in the thoracic “wilds”: Carcinoid, large cell neuroendocrine, and thymomas HMP Education
18:06 EGFR inhibitors in mutation (+) patients: Current therapeutic strategies in the frontline setting HMP Education
19:53 Managing progression in EGFR-mutant NSCLC patients: Potential impact of 2nd and 3rd generation TKIs? HMP Education
17:47 Communicating with patients and families: Managing expectations as hope and reality collide HMP Education
